For patients with chronic kidney disease, dose adjustments for other medications requires coordination with other specialists to maintain treatment efficacy, explained Linda Awdishu, PharmD, FASN, professor and division head of clinical pharmacy at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences.
Patients with chronic kidney disease may be on multiple medications that need to be adjusted, which requires coordination with other specialists who may have prescribed those drugs, explained Linda Awdishu, PharmD, FASN, professor and division head of clinical pharmacy at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences.
Transcript
How do you balance drug benefits with kidney disease risks, and how often might dose adjustments have to take place?
So, I currently practice in the University of California, San Diego, Chronic Kidney Disease Clinic, and I see patients who have chronic kidney disease, and the kidney disease ranges from stage II to V. And so, for every single patient that comes to clinic, we evaluate their medications. We look at whether there's a need for a dose adjustment and assess the presence of adverse events from that medication. And so then, that all that information comes into play into a risk assessment.
Where it becomes challenging is you may have certain drugs that are prescribed by other specialties, and they may require a dose adjustment, but as the nephrologist, we shouldn't be just adjusting the dose without discussion with those specialties. An example would be if a patient is prescribed an antidepressant, and there's a recommendation to reduce the dose by 25% or 50%, even. Many of these recommendations in the drug compendia are a little vague, right? And it may be difficult to assess the adverse events like patients may say, “I feel perfectly fine, I have no side effects.” So, do we want to risk kind of losing the efficacy of that antidepressant when the patient's tolerating the medication?
And so that's kind of the risk assessment we make, and then we always work with the specialty providers to make recommendations and get their input on whether they feel comfortable reducing the dose in that specific individual.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen